Skip to main content
Open this photo in gallery:

Doses of the Pfizer-BioNTech vaccine against COVID-19 for children are prepared at a children doctor's practice in Maintal near Frankfurt, Germany, Dec. 15, 2021.KAI PFAFFENBACH/Reuters

Pfizer Inc Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.

Pfizer/BioNtech’s COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily mutated Omicron variant but less effective in preventing transmission.

With cases soaring, some countries have expanded COVID-19 vaccine booster programs or shortened the gap between shots as governments scramble to shore up protection.

After recovering from Omicron, what comes next is complicated

Canada to re-examine definition of fully vaccinated once more people have had boosters

Opinion: Newfoundland and Labrador’s culture has helped it achieve Canada’s highest vaccination rate

In an interview with Israel’s N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.

“This will not be a good scenario. What I’m hoping (is) that we will have a vaccine that you will have to do once a year,” Bourla said.

“Once a year - it is easier to convince people to do it. It is easier for people to remember.

“So from a public-health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn’t forget the other variants and that could be a solution,” Bourla said.

Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.

Citing three studies, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday that a third dose of an mRNA vaccine is key to fighting Omicron, providing 90-per-cent protection against hospitalization.

A preliminary study published by Israel’s Sheba Medical Center on Monday found that a fourth shot increases antibodies to even higher levels than the third but was likely not enoughto fend off Omicron. Nonetheless, a second booster was still advised for risk groups, Sheba said.

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe